Crossmark

Circulating heparan sulfate chains and body weight contribute to anti-Xa levels in cancer patients using the prophylactic dose of enoxaparin

Published Online: 2020-05-06

Published Print: 2020-07

Authors

Maurice-Dror, Corinne

Litvak, Michael

Keren-Politansky, Anat

Ackerman, Shanny

Haim, Nissim

Nadir, Yona
License Information

Text and Data Mining valid from 2020-05-06

Version of Record valid from 2020-05-06
More Information

Article History

First Online: 6 May 2020

Compliance with ethical standards

:

: No conflict of interest to declare.

Document is current